National Disease Research Interchange Receives Funding Commitment For Rare Disease Initiative; Genzyme Corporation Pledges $250,000 To Support NDRI’s New National Rare Disease Biomaterials Resource

PHILADELPHIA--(BUSINESS WIRE)--Building on a longstanding relationship, Genzyme Corporation has presented a check for $50,000, the first of a five-year installment to the National Disease Research Interchange to support the growth and development of NDRI’s new National Rare Disease Biomaterials Resource. The program will expand on NDRI’s successful rare disease pilot initiative to provide human tissue resources for investigators in the field of rare diseases.